SCHEMBL20047503

SCHEMBL20047503

CCCCCCC(C)(CCCC)CCC(=O)OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 2/20 0.46
CA14 Q9ULX7 2/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
POLB P06746 1/20 0.45
POLA1 P09884 1/20 0.45
TSHR P16473 3/20 0.43
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 1/20 0.41
ATM Q13315 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM5A P29375 2/20 0.41
HPGD P15428 1/20 0.41
RECQL P46063 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PAM P19021 2/20 0.41
DGKA P23743 1/20 0.40
EPHX1 P07099 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23502561 1.00 CA12 (0.46) CA12CA14CA2CA7CA9
Ammonia Solution, Strong SCHEMBL28792662 0.96 CA12 (0.46) CA12CA14CA2CA7CA9
SCHEMBL21654316 0.93 PAM (0.49) CA12CA14CA2CA7CA9
SCHEMBL20047564 0.91 CA12 (0.45) CA12CA14CA2CA7CA9
Ammonia Solution, Strong SCHEMBL28792667 0.89 TSHR (0.48) CA12CA14CA2CA7CA9
SCHEMBL20076183 0.84 MAPT (0.47) TSHRMEN1KMT2AMAPTATM
SCHEMBL23944939 0.84 MAPT (0.47) TSHRMEN1KMT2AMAPTATM
SCHEMBL12504537 0.84 DGKA (0.41) TSHRMEN1KMT2AMAPTATM
SCHEMBL12504163 0.84 DGKA (0.41) TSHRMEN1KMT2AMAPTATM
SCHEMBL19176823 0.84 MEN1 (0.49) CA12CA14CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2019-10-22 US disclosed
US-20190151403-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF S&T GLOBAL INC. 2019-05-23 US disclosed
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10450306-B2 Isoxazole analogs as FXR agonists and methods of use thereof GPBAR1, SLC10A1, NR1H4 CA12 3445/4885CA14 3222/4885CA2 2228/4885
US-20180099957-A1 ISOXAZOLE ANALOGS AS FXR AGONISTS AND METHODS OF USE THEREOF GPBAR1, SLC10A1, NR1H4 CA12 3445/4885CA14 3222/4885CA2 2228/4885
US-20190151403-A1 NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF MALT1, MYLK2, FKBP1B CA12 2159/4885CA14 3090/4885CA2 1322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.